These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27131967)

  • 1. Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility.
    Calmasini FB; Alexandre EC; Silva FH; De Nucci G; Antunes E; D'Ancona CA; Mónica FZ
    Urology; 2016 Aug; 94():312.e9-312.e15. PubMed ID: 27131967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
    Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
    BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
    Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
    J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
    Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.
    Britt RD; Thompson MA; Kuipers I; Stewart A; Vogel ER; Thu J; Martin RJ; Pabelick CM; Prakash YS
    Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L537-42. PubMed ID: 26254425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra.
    Toque HA; Antunes E; Teixeira CE; De Nucci G
    Urology; 2008 Sep; 72(3):711-5. PubMed ID: 18359064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
    Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
    Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
    Füllhase C; Hennenberg M; Sandner P; Strittmatter F; Niedworok C; Bauer RM; Gratzke C; Soler R; Stief C; Andersson KE
    Neurourol Urodyn; 2015 Nov; 34(8):787-93. PubMed ID: 25230878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
    Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
    Free Radic Res; 2015; 49(12):1479-87. PubMed ID: 26334090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
    Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
    PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator.
    Priviero FB; Baracat JS; Teixeira CE; Claudino MA; De Nucci G; Antunes E
    Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):728-34. PubMed ID: 16173929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1093-102. PubMed ID: 17596536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms.
    Teixeira CE; Priviero FB; Todd J; Webb RC
    Hypertension; 2006 Mar; 47(3):596-602. PubMed ID: 16391173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
    Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
    Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
    Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
    Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
    Bice JS; Keim Y; Stasch JP; Baxter GF
    Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
    Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
    Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant.
    Tawa M; Yamashita Y; Masuoka T; Nakano K; Yoshida J; Nishio M; Ishibashi T
    J Pharmacol Sci; 2019 May; 140(1):43-47. PubMed ID: 31036520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.